A team at the Biohub reported that co‑administering a three‑amino‑acid cocktail with lipid nanoparticles (LNPs) markedly improved in vivo mRNA delivery and CRISPR editing efficiency in preclinical models. The study, published in Science Translational Medicine, links cellular metabolic state to LNP uptake and shows a pragmatic way to enhance therapeutic payload delivery without redesigning nanoparticle chemistry. The approach could be rapidly adopted across LNP platforms to increase potency and lower dose requirements, but regulators and developers will demand reproducibility, safety profiling of the supplement strategy, and demonstration across tissue targets before clinical translation. The result addresses a major translational bottleneck for nucleic acid therapeutics.